Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks for the assurances winnerpicker! Yep, it’s the times like these that tests one’s faith - but, my only worry is trying to buy more. .. at these fire sale prices!
Nice! Thanks MjMilo and HorizenBull!!! $$$OWCP$$$ Plus, I bet GW*^ is watching OWCP like a Hawk because of the nasal spray and the tablet!!!
We have the meats! $$$ OWCP $$$
TappyS
Skin Rashes alone would be huge!!! $$$OWCP$$$
The OWCP (psoriasis) ointment is also intended to treat inflammatory skin diseases and conditions. What are the potential inflammatory skin diseases we are talking about here for OWCP? FYI:
“Inflammatory skin diseases are the most common problem in dermatology. They come in many forms, from occasional rashes accompanied by skin itching and redness, to chronic conditions such as dermatitis (eczema), rosacea, seborrheic dermatitis, and psoriasis. Skin inflammation can be characterized as acute or chronic.”
$$$OWCP$$$
This bears repeating!!! Muscle Spasticity in MS? Huge need, huge market. $$$OWCP$$$
https://multiplesclerosisnewstoday.com/2018/12/20/cannabis-based-sublingual-tablet-enter-trials-israel-possible-spaticity-treatment-owc-pharmaceuticals/
This bears repeating!!! Muscle Spasticity in MS? Huge need, huge market. $$$OWCP$$$
Source: Wall Street Journal Editorial Board Article - credit where credit is due.
Big Pharma’s Cancer Race
After tax reform, companies invest in innovation rather than tax arbitrage.
SHARE
By The Editorial Board
Jan. 9, 2019 7:17 p.m. ET
Not long ago America’s political class was fretting about too many “me-too” drugs. Eli Lilly ’s bid for Loxo Oncology , which follows a flurry of biotech deals, shows how the pharmaceutical landscape is fast-evolving as U.S. drug companies compete to become leaders in oncology.
Indianapolis-based Eli Lilly on Monday announced plans to purchase the Stamford, Conn., start-up Loxo for $8 billion with the goal of expanding its oncology portfolio. Loxo has pioneered an experimental therapy targeting single-gene abnormalities that can cause tumors throughout the body. Most cancer treatments target specific body sites, so Loxo’s innovation may be revolutionary.
In November Loxo’s Vitrakvi became the first tumor-agnostic treatment to receive FDA approval. Three-quarters of patients in clinical trials responded to the drug, which targets a rare gene “fusion.” The market for Vitrakvi may be small, but Lilly’s backing will help bring the drug to more patients.
Lilly and other pharmaceutical giants are seeking to develop novel oncology treatments as expiring patents undercut profit margins on their blockbusters. Last June Lilly bought Armo Biosciences, a trailblazer in immunotherapy treatments that harness the body’s immune system to fight cancer. Lilly CFO Josh Smiley says a lower corporate tax rate is helping his company compete with foreign rivals for biotech start-ups.
Recall how U.S. drug makers a few years ago sought to exploit lower rates abroad with corporate inversions. The GOP corporate tax reform, which cut the U.S. rate to 21% from 35% and allowed businesses to repatriate overseas profits tax-free, has given U.S. drug makers more cash to invest. Now they’re acquiring companies to advance innovation rather than engage in tax arbitrage as they did pre-reform.
I second your opinion!!! The quiet before the launch!
$OWCP$
Great to see you folks chiming in today! OWCP will make us all seem smarter than we really are - and soon!
Oh, Well! I’ll buy more cheapies then! $$$OWCP$$$
Watch things end on a green note!!! $$$OWCP$$$
TappyS
Nice comments kbaz! I’m pretty sure Dr. Baruch gave a talk in the Czech Republic (Prague) last year about opioid mortality and using medical cannabis to mitigate pain in certain applications and prevent opioid OD deaths.
So, I think that will be front and center on OWCP’s goals to make the world a better place ASAP!
$$$OWCP$$$
TappyS
Slapped the Ask three times today! $$$OWCP$$$
Tied for 6th as most posted board -$$$OWCP$$$
New updates on their studies, new patent application news plus, stock market in general - that’s what - if history is any indicator that is. $$$OWCP$$$
Yep, that’s my take on it, too! Mind the Gap! $$$OWCP$$$
Agreed- Business news today is very bullish on the economy, so the rising tides will lift almost all boats, esp. $$$OWCP$$$!!!
OWCP is “absolutely fascinating”...
Fortune favors the Bulls!
https://www.marketwatch.com/press-release/2018-was-a-big-year-for-cannabis-2019-could-be-bigger-2019-01-03
I hope massive buys today because: 1) people can buy before the conference, and 2) people going to the conference, in order to get cheaper plane tickets, are flying out today, and buying today while hanging at airports, and 3) probably telling their business associates to buy OWCP today - knowing full well that an 8-K is TBA today or Monday!!!
Green Day today - no problem!
TappyS
Ka-Ching!!! Multi-Billion dollar company trading for $0.14/share?
Hello, McFly!!!
Great DD moxa1!!! And it reduces fine lines and wrinkles around the mouth for 81% of patients? Holy Crap Batman - to the Bat Cave!!!
Go OWCP Go!!!
TappyS
The stars are aligned, moxa1! OWCP is going to fill our sails, and make the World a better place!
TappyS
wanted to share a story with you from Regina Leader-Post: OWC Pharmaceutical Research Corp. granted patent for topical formulations in Czech Republic Psoriasis has an unpredictable course of symptoms, a number of external triggers and significant comorbidities https://leaderpost.com/cannabis-business/cannabis-experts/owc-pharmaceutical-research-corp-granted-patent-for-topical-formulations-in-czech-republic/wcm/e48d3fca-454a-4c82-a485-be84807cbc82
People will be ponying up - even while on vacation this week! OWCP for you and me!!!
With Ya! Wheeee!!! OWCP is in turbo drive!
This makes Israeli companies stronger for investment vs. US stocks, so in the long run it’s yet another reason to be in OWCP now.
I don’t know if I could handle it, but I’m sure willing to go there! Fortune favors the Bulls! Go $$$OWCP$$$!!!
TappyS
Hi skitahoe, Well, I guess the changes reflect tweets made to get their drug products to be successful in the R&D efforts. Also, another thought is maybe these are the more accurate goals/endpoints which were potentially “under wraps” to keep things proprietary and insure success.
I like your quarterly updates via conference calls or webcasts ideas. That will be implemented someday, probably when they have more staff and income and expenses to report.
Cheers!
TappyS
Very good indicators indeed! Go OWCP - To Infinity and Beyond!!!
The OWCP Investor Presentation looks new to me? Can folks tell?
Thanks!
TappyS
Agreed! Hell, yeah! January two years ago - we hurdled that level - I believe, in a week? Psoriasis is a $7B market opportunity world-wide. Multi-dollars share price, would be easily made for those kind of variables.
Over a dollar by March, like two years ago - no prob!
I predict a grand slam home run on the Ph 1 results! Ka-Ching!!! OWCP!!!
I think before the Conference news on the completion of the Ph. 1 and the results will be shared with the world!
Nice! It will be back at #1 soon - OWCP!!!
Psoriasis Ointment interview with Dr. Sharon Rosenblat
https://www.yahoo.com/amphtml/finance/news/cfn-media-exclusive-interview-owcps-123000279.html
Ka-boom! $$$OWCP$$$
GW*^ will be in San Fran at the JP Morgan Conference at the same time as OWCP will be in San Fran. It’s interesting they only announced this today... hmmm...
GW Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
Source: GlobeNewswire Inc.
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW’s Chief Executive Officer, will present a company update at the J.P. Morgan 2019 Healthcare Conference in San Francisco, Calif. on Tuesday, January 8, 2019 at 7:30 a.m. PST (10:30 a.m. EST), followed by a Q&A session.
A live audio webcast of the presentation will be available through GW’s corporate website in the investor relations section from the investor’s calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.
About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW, along with its U.S. subsidiary Greenwich Biosciences, has received U.S. FDA approval for EPIDIOLEX (cannabidiol) oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older and which is now available by prescription in the U.S. The Company has submitted a regulatory application in Europe for the adjunctive treatment of seizures associated with LGS and Dravet syndrome. The company continues to evaluate EPIDIOLEX in additional rare epilepsy conditions and currently has an ongoing clinical trial in tuberous sclerosis complex (TSC). GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex® (nabiximols), which is approved for the treatment of spasticity due to multiple sclerosis in numerous countries outside the United States and for which the company is now planning a U.S. Phase 3 trial. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for epilepsy, glioblastoma, and schizophrenia. For further information, please visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc
Stephen Schultz, VP Investor Relations 917 280 2424 / 401 500 6570